DelveInsight’s, “Metastatic Castration-Resistant Prostate Cancer Pipeline Insight 2023,” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Metastatic Castration-Resistant Prostate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Metastatic Castration Resistant Prostate Cancer Emerging drugs, the Metastatic Castration Resistant Prostate Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Metastatic Castration Resistant Prostate Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Metastatic Castration Resistant Prostate Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Metastatic Castration Resistant Prostate Cancer clinical trials studies, Metastatic Castration Resistant Prostate Cancer NDA approvals (if any), and product development activities comprising the technology, Metastatic Castration Resistant Prostate Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Metastatic Castration Resistant Prostate Cancer Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Metastatic Castration Resistant Prostate Cancer Pipeline landscape @ Metastatic Castration Resistant Prostate Cancer Pipeline Outlook Report
Metastatic Castration Resistant Prostate Cancer Overview
Prostate cancer (PCa) is one of the most prevalent malignancies in the world and the third most common cause of male cancer-related death in the United States of America (USA). The majority of men with newly diagnosed PCa present with localized disease and undergo radical prostatectomy and/or radiological therapy, followed by androgen deprivation therapy (ADT). Depending on the grade of the cancer, a variable percentage of these patients experience progression to castration-resistant prostate cancer (CRPC) within 10 years.
Recent Developmental Activities in the Metastatic Castration-Resistant Prostate Cancer Treatment Landscape
For further information, refer to the detailed Metastatic Castration Resistant Prostate Cancer Drugs Launch, Metastatic Castration Resistant Prostate Cancer Developmental Activities, and Metastatic Castration Resistant Prostate Cancer News, click here for Metastatic Castration Resistant Prostate Cancer Ongoing Clinical Trial Analysis
Metastatic Castration Resistant Prostate cancer Emerging Drugs
SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39 in the tumor microenvironment, allowing for a dual mechanism of action to promote anti-tumor immunity via reduction of immunosuppressive adenosine in addition to increasing levels of immunostimulatory ATP. SRF617 has been granted Orphan Drug designation for the treatment of advanced pancreatic cancer by the FDA.
Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway.
HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.
Metastatic Castration Resistant Prostate Cancer Therapeutic Assessment
There are approx. 75+ key companies which are developing the therapies Metastatic Castration Resistant Prostate cancer. The companies which have their Metastatic Castration Resistant Prostate cancer drug candidates in the most advanced stage, i.e phase III include Clovis Oncology.
Find out more about the Metastatic Castration Resistant Prostate Cancer Pipeline Segmentation, Therapeutics Assessment, and Metastatic Castration Resistant Prostate Cancer Emerging Drugs @ Metastatic Castration Resistant Prostate Cancer Treatment Landscape
Scope of the Metastatic Castration-Resistant Prostate Cancer Pipeline Report
Dive deep into rich insights for drugs for Metastatic Castration Resistant Prostate Cancer Pipeline Companies and Therapies, click here @ Metastatic Castration Resistant Prostate Cancer Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Metastatic Castration Resistant Prostate Cancer Mergers and acquisitions, Metastatic Castration Resistant Prostate Cancer Licensing Activities @ Metastatic Castration Resistant Prostate Cancer Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: 09193216187Address:304 S. Jones Blvd #2432, City: Las VegasState: United StatesCountry: IndiaWebsite: https://www.delveinsight.com/